Summary
The current demand for early intervention, prevention, and treatment of late onset Alzheimer’s disease (LOAD) warrants deeper understanding of the underlying molecular processes which could contribute to biomarker and drug target discovery. Utilizing high-throughput proteomic measurements in serum from a prospective population-based cohort of older adults (n=5,294), we identified 303 unique proteins associated with incident LOAD (median follow-up 12.8 years). Over 40% of these proteins were associated with LOAD independently of APOE-ε4 carrier status. These proteins were implicated in neuronal processes and overlapped with protein signatures of LOAD in brain and cerebrospinal fluid. We found 17 proteins which LOAD-association was strongly dependent on APOE-ε4 carrier status. Most of them showed consistent associations with LOAD in cerebrospinal fluid and a third had brain-specific gene expression. Remarkably, four proteins in this group (TBCA, ARL2, S100A13 and IRF6) were downregulated by APOE-ε4 yet upregulated as a consequence of LOAD as determined in a bi-directional Mendelian randomization analysis, reflecting a potential response to the disease onset. Accordingly, the direct association of these proteins to LOAD was reversed upon APOE-ε4 genotype adjustment, a finding which we replicate in an external cohort (n=719). Our findings provide an insight into the dysregulated pathways that may lead to the development and early detection of LOAD, including those both independent and dependent on APOE-ε4. Importantly, many of the LOAD-associated proteins we find in the circulation have been found to be expressed - and have a direct link with AD - in brain tissue. Thus, the proteins identified here, and their upstream modulating pathways, provide a new source of circulating biomarker and therapeutic target candidates for LOAD.
Competing Interest Statement
L.L.J., A.P.O and J.J.L are employees and stockholders of Novartis. N.T.S and A.I.L are co-founders of Emtherapro. No other potential conflicts of interest relevant to this article were reported.
Funding Statement
The National Institute on Aging (NIA) contracts N01-AG-12100 and HHSN271201200022C for V.G. financed the study. IHA received a grant from Althingi (the Icelandic Parliament), V.G. received funding from the NIA (1R01AG065596-01A1) and E.J. from the NIA (1K08AG068604). A.I.L was also funded from the NIA (P30AG066511 and U01AG061357). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Genome Research at Ace Alzheimer Center Barcelona project (GRACE) is supported by Grifols SA, Fundacion bancaria ‘La Caixa’, Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de analisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generacion de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Accion Estrategica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER ‘Una manera de hacer Europa’) grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nr AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nr PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Amanda Cano received support from the ISCIII under the grant Sara Borrell (CD22/00125).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The AGES study was approved by the NBC in Iceland (approval number VSN-00-063), and by the National Institute on Aging Intramural Institutional Review Board, and the Data Protection Authority in Iceland.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
